Logo do repositório
 
Publicação

A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains

2021Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorTorres, Tiago
dc.contributor.authorBarcelos, Anabela
dc.contributor.authorFilipe, Paulo
dc.contributor.authorFonseca, João Eurico
dc.date.accessioned2021-12-03T16:58:46Z
dc.date.available2021-12-03T16:58:46Z
dc.date.issued2021
dc.descriptionCopyright © 2021 Torres, Barcelos, Filipe and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.pt_PT
dc.description.abstractIntroduction: Several new treatments have been developed for psoriatic disease, an inflammatory condition that involves skin and joints. Notwithstanding, few studies have made direct comparisons between treatments and therefore it is difficult to select the ideal treatment for an individual patient. The aim of this systematic review with network meta-analysis (NMA) was to analyze available and approved biologic therapies for each domain of psoriatic disease: skin, peripheral arthritis, axial arthritis, enthesitis, dactylitis, and nail involvement. Methods: Data from randomized clinical trials (RCTs) were included. A systematic review was performed using the MEDLINE database (July 2020) using PICO criteria. Bayesian NMA was conducted to compare the clinical efficacy of biological therapy in terms of the American College of Rheumatology criteria (ACR, 24 weeks) and Psoriasis Area and Severity Index (PASI, 10-16 weeks). Results: Fifty-four RCTs were included in the systematic review. Due to the design of the RCTs, namely, outcomes and time points, network meta-analysis was performed for skin and peripheral arthritis domains. For the skin domain, 30 studies reporting PASI100 were included. The peripheral arthritis domain was analyzed through ACR70 in 12 studies. From the therapies approved for both domains, secukinumab and ixekizumab were the ones with the highest probability of reaching the proposed outcomes. There is a lack of outcome uniformization in the dactylitis, enthesitis, and nail domains, and therefore, an objective comparison of the studies was not feasible. Nevertheless, secukinumab was the treatment with the best compromise between the number of studies in each domain and the results obtained in the different outcomes. Conclusion: Secukinumab and ixekizumab were the treatments with the highest probability of reaching both PASI100 and ACR70 outcomes. Due to the lack of a standard evaluation of outcomes of the other psoriatic disease domains, a network meta-analysis for all the domains was not possible to perform.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFrontiers in medicine, 7, 618163pt_PT
dc.identifier.doi10.3389/fmed.2020.618163pt_PT
dc.identifier.eissn2296-858X
dc.identifier.urihttp://hdl.handle.net/10451/50277
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/medicine#pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectPsoriasispt_PT
dc.subjectPsoriatic arthritispt_PT
dc.subjectPsoriatic diseasept_PT
dc.subjectBiologic therapypt_PT
dc.subjectSystematic reviewpt_PT
dc.subjectNetwork meta-analysispt_PT
dc.titleA systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domainspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Medicinept_PT
oaire.citation.volume7pt_PT
person.familyNameTorres
person.familyNameFilipe
person.familyNameFonseca
person.givenNameTiago
person.givenNamePaulo
person.givenNameJoão
person.identifier.ciencia-idFF1B-8834-7AE0
person.identifier.ciencia-id171A-309C-C397
person.identifier.ciencia-idF310-B85D-57C7
person.identifier.orcid0000-0003-0404-0870
person.identifier.orcid0000-0002-7337-6493
person.identifier.orcid0000-0003-1432-3671
person.identifier.scopus-author-id7003448874
person.identifier.scopus-author-id7101983519
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication4710c8a1-f368-44c4-a825-8f64ea981ae2
relation.isAuthorOfPublicationac4119d7-4c3c-471a-9723-f8b8e7543f55
relation.isAuthorOfPublication1772dc12-7c55-4c76-ae2d-c23270172480
relation.isAuthorOfPublication.latestForDiscoveryac4119d7-4c3c-471a-9723-f8b8e7543f55

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Biologic_psoriatic.pdf
Tamanho:
1.98 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM-CUR-Artigos em Revistas Internacionais